In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists

Drug and Alcohol Dependence

Volumn 59, Issue 1, 2000, Pages 1-15

  Bisaga, Adam ^a   Popik, Piotr ^b  

^a Columbia University ^*  (United States)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Alcohol; NMDA receptor antagonists; Opiates; Pharmacotherapy; Psychostimulants

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; ACAMPROSATE; ALCOHOL; AMANTADINE; AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; COCAINE; CYCLOSERINE; DEXTROMETHORPHAN; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IBOGAINE; KYNURENIC ACID; LAMOTRIGINE; MEMANTINE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NITRIC OXIDE SYNTHASE INHIBITOR; TIZANIDINE;

ALCOHOLISM; ALEXITHYMIA; ANIMAL MODEL; DETOXIFICATION; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; HEROIN DEPENDENCE; HUMAN; LOCOMOTION; NEUROTRANSMISSION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RECURRENCE RISK; REINFORCEMENT; REVIEW; SENSITIZATION; WITHDRAWAL SYNDROME;

EID: 0034004755     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(99)00107-6     Document Type: Review

References (157)

1. Alterman, A.I., Droba, M., Antelo, R.E., Cornish, J.W., Sweeney, K.K., Parikh, G.A., O'Brien, C.P., 1992. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. 31, 19-29.
2. Ball, J.C., Ross, A., 1991. The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. Springer-Verlag, New York.
3. Bem, J.L., Peck, R., 1992. Dextromethorphan. An overview of safety issues. Drug Saf. 7, 190-199.
4. Berton, F., Francesconi, W.G., Madamba, S.G., Zieglgansberger, W., Siggins, G.R., 1998. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin. Exp. Res. 22, 183-191.
5. Bespalov, A., 1996. The expression of both amphetamine-conditioned place preference and pentylenetetrazol-conditioned place aversion is attenuated by the NMDA receptor antagonist ( + / - )-CPP. Drug Alcohol Depend. 41, 85-88.
6. Bespalov, A., Zvartau, E., 1996a. Effect of kynurenic acid on the acquisition of intravenous morphine self-administration in rats. Biull. Eksp. Biol. Med. 122, 54-56.
7. Bespalov, A.Y., Zvartau, E., 1996b. Intraaccumbens administration of NMDA receptor antagonist ( + / - )-CPP prevents locomotor activation conditioned by morphine and amphetamine in rats. Pharmacol. Biochem. Behav. 55, 203-207.
8. Bespalov, A., Zvartau, E., 1997. NMDA receptor antagonists prevent conditioned activation of intracranial self-stimulation in rats. Eur. J. Pharmacol. 326, 109-112.
9. Bespalov, A., Dumpis, M., Piotrovsky, L., Zvartau, E., 1994. Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. Eur. J. Pharmacol. 264, 233-239.
10. Biala, G., Langwinski, R., 1996. Rewarding properties of some drugs studied by place preference conditioning. Pol. J. Pharmacol. 48, 425-430.
11. Bisaga, A., Gianelli, P., Popik, P., 1997. Opiate withdrawal with dextromethorphan. Am. J. Psychiatry 154, 584.
12. Bozarth, M.A., Pudiak, C.M., Morris, M., 1994. Nitric oxide synthesis inhibition does not affect brain stimulation reward. Pharmacol. Biochem. Behav. 48, 487-490.
13. Brewer, D.D., Catalano, R.F., Haggerty, K., Gainey, R.R., Fleming, C.B., 1998. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 93, 73-92.
14. Bristow, L.J., Hogg, J.E., Hutson, P.H., 1997. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology 36, 241-250.
15. Cappendijk, S.L., Dzoljic, M.R., 1993. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol. 241, 261-265.
16. Carey, R.J., Dai, H., Krost, M., Huston, J.P., 1995. The NMDA receptor and cocaine: evidence that MK-801 can induce behavioral sensitization effects. Pharmacol. Biochem. Behav. 51, 901-908.
17. Carlezon, W.A., Jr. Wise, R.A., 1993. Morphine-induced potentiation of brain stimulation reward is enhanced by MK-801. Brain Res. 620, 339-342.
18. Carroll, K.M., Nich, C., Rounsaville, B.J., 1995. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J. Nerv. Ment. Dis. 183, 251-259.
19. Cascella, N.G., Macciardi, F., Cavallini, C., Smeraldi, E., 1994. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J. Neural Transm. Gen. Sect. 95, 105-111.
20. Cervo, L., Samanin, R., 1996. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res. 731, 31-38.
21. Childress, A.R., McLellan, A.T., O'Brien, C.P., 1986. Role of conditioning factors in the development of drug dependence. Psychiatr. Clin. N. Am. 9, 413-425.
22. Collins, E.D., Ward, A.S., McDowell, D.M., Foltin, R.W., Fischman, M.W., 1998. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav. Pharmacol. 9, 587-598.
23. Corbett, D., 1989. Possible abuse potential of the NMDA antagonist MK-801. Behav. Brain Res. 34, 239-246.
24. Damianopoulos, E.N., Carey, R.J., 1995. Evidence for N-methyl-D-aspartate receptor mediation of cocaine induced corticosterone release and cocaine conditioned stimulant effects. Behav. Brain Res. 68, 219-228.
25. Danysz, W., Parsons, C.G., 1998. Glycine and NMDA receptors-physiological significance and possible therapeutic applications. Pharmacol. Rev. 50, 597-664.
26. Danysz, W., Dyr, W., Jankowska, E., Glazewski, S., Kostowski, W., 1992. The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin. Exp. Res. 16, 499-504.
27. Danysz, W., Zajaczkowski, W., Parsons, C.G., 1995. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6, 455-474.
28. Danysz, W., Parsons, C.G., Kornhuber, J., Schmidt, W.J., Quack, G., 1997. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21, 455-468.
29. Di Chiara, G., Tanda, G., Cadoni, C., Avquas, E., Bassareo, V., Carboni, E., 1998. Homologies and differences in the action of drugs of abuse and a conventional reinforcer (food) on dopamine transmisson: an interpretative framework of the mechanism of drug dependence. Adv. Pharmacol. 42, 983-987.
30. Del Pozo, E., Barrios, M., Baeyens, J.M., 1996. The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine induced place preference conditioning in mice. Psychopharmacology (Berlin) 125, 209-213.
31. Dingledine, R., Borges, K., Bowie, D., Traynelis, S.F., 1999. The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-62.
32. Dole, V.P., Nyswander, M., 1965. A medical treatment for diacetylmorphine (heroin) addiction. J. Am. Med. Assoc. 193, 80-84.
33. Elliott, K., Kest, B., Man, A., Kao, B., Inturrisi, C.E., 1995. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology 13, 347-356.
34. Fidecka, S., Langwinski, R., 1989. Interaction between ketamine and ethanol in rats and mice. Pol. J. Pharmacol. 41, 23-32.
35. Fitzgerald, L.W., Ortiz, J., Hamedani, A.G., Nestler, E.J., 1996. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J. Neurosci. 16, 274-282.
36. Garbutt, J.C., West, S.L., Carey, T.S., Lohr, K.N., Crews, F.T., 1999. Pharmacological treatment of alcohol dependence, a review of the evidence. J. Am. Med. Assoc. 281, 1318-1325.
37. Gold, M.S., Redmond, D.E., Kleber, H.D. Jr, 1978. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2, 599-602.
38. Greenstein, R.A., Arndt, I.C., McLellan, A.T., O'Brien, C.P., Evans, B., 1984. Naltrexone: a clinical perspective. J. Clin. Psychiatry 45, 25-28.
39. Handelsman, L., Aronson, M.J., Ness, R., Cochrane, K.J., Kanof, P.D., 1992. The dysphoria of heroin addiction. Am. J. Drug Alcohol Abuse 18, 275-287.
40. Handelsman, L., Limpitlaw, L., Williams, D., Schmeidler, J., Paris, P., Stimmel, B., 1995. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend. 39, 173-180.
41. Haracz, J.L., MacDonall, J.S., Sircar, R., 1997. Effects of nitric oxide synthase inhibitors on cocaine sensitization. Brain Res. 746, 183-189.
42. Herberg, L.J., Rose, I.C., 1989. The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward. Psychopharmacology (Berlin) 99, 87-90.
43. Herman, B.H., O'Brien, C.P., 1997. Clinical medication development for opiate addiction: focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Semin. Neurosci. 9, 158-172.
44. Herman, B.H., Vocci, F., Bridge, P., 1995. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology 13, 269-293.
45. Herrling, P.L., 1997. Excitatory amino acids: clinical results with antagonists. Academic Press, San Diego.
46. Hesselink, M.B., Smolders, H., De Boer, A.G., Breimer, D.D., Danysz, W., 1999. Modification of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and ( + )MK-801 after chronic administration. Behav. Pharmacol. 10, 85-98.
47. Heyser, C.J., Schulteis, G., Durbin, P., Koob, G.F., 1998. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18, 125-133.
48. Higgins, G.A., Nguyen, P., Sellers, E.M., 1992. The NMDA antagonist dizocilpine (MK-801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci. 50, PL167-PL172.
49. Hoffman, D.C., 1994. The noncompetitive NMDA antagonist MK-801 fails to block amphetamine- induced place conditioning in rats. Pharmacol. Biochem. Behav. 47, 907-912.
50. Holter, S.M., Danysz, W., Spanagel, R., 1996. Evidence for alcohol anti-craving properties of memantine. Eur. J. Pharmacol. 314, R1-2.
51. Inturrisi, C.E., 1997. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependece. Semin. Neurosci. 9, 110-119.
52. Isbel, H., Fraser, H.F., 1953. Actions and addiction liabilities of dromoran derivatives in man. J. Pharmacol. Exp. Ther. 106, 524-530.
53. Itzhak, Y., 1997. Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase. J. Pharmacol. Exp. Ther. 282, 521-527.
54. Jasinski, D.R., Johnson, R.E., Kocher, T.R., 1985. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch. Gen. Psychiatry 42, 1063-1066.
55. Jeziorski, M., White, F.J., Wolf, M.E., 1994. MK-801 prevents the development of behavioral sensitization during repeated morphine administration. Synapse 16, 137-147.
56. Kalivas, P.W., Striplin, C.D., Steketee, J.D., Klitenick, M.A., Duffy, P., 1992. Cellular mechanisms of behavioral sensitization to drugs of abuse. Ann. N. Y. Acad. Sci. 654, 128-135.
57. Kampman, K., Volpicelli, J.R., Alterman, A., Cornish, J., Weinrieb, R., Epperson, L., Sparkman, T., O'Brien, C.P., 1996. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 41, 25-33.
58. Karcz-Kubicha, M., Liljequist, S., 1995. Effects of post-ethanol administration of NMDA and non-NMDA receptor antagonists on the development of ethanol tolerance in C57B1 mice. Psychopharmacology (Berlin) 120, 49-56.
59. Khanna, J.M., Wu, P.H., Weiner, J., Kalant, H., 1991. NMDA antagonist inhibits rapid tolerance to ethanol. Brain Res. Bull. 26, 643-645.
60. Khanna, J.M., Morato, G.S., Chau, A., Shah, G., 1995. D-cycloserine enhances rapid tolerance to ethanol motor incoordination. Pharmacol. Biochem. Behav. 52, 609-614.
61. Kim, H.S., Park, W.K., 1995. Nitric oxide mediation of cocaine-induced dopaminergic behaviors: ambulation-accelerating activity, reverse tolerance and conditioned place preference in mice. J. Pharmacol. Exp. Ther. 275, 551-557.
62. Kleber, H.D., 1999. Opioids: detoxification. In: Galanter, M., Kleber, H.D. (Eds.), Textbook of Substance Abuse Treatment. American Psychiatric Press, Washington DC, pp. 251-269.
63. Kolar, A.F., Brown, B.S., Weddington, W.W., Haertzen, C.C., Michaelson, B.S., Jaffe, J.H., 1992. Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. Int. J. Addict. 27, 849-868.
64. Kornhuber, J., Weller, M., 1997. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 41, 135-144.
65. Kornhuber, J., Weller, M., Schoppmeyer, K., Riederer, P., 1994. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J.Neural Transm. Suppl. 43, 91-104.
66. Kosten, T.R., Morgan, C.M., Falcione, J., Schottenfeld, R.S., 1992. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry 49, 894-898.
67. Kotlinska, J., Liljequist, S., 1996. Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Psychopharmacology (Berlin) 127, 238-244.
68. Kovera, C.A., Kovera, M.B., Singleton, E.G., Ervin, F.R., Williams, I.C., Mash, D.C., 1998. Decreased drug craving during inpatient detoxification with ibogaine. NIDA Res. Monogr. 179, 294.
69. Koyuncuoglu, H., 1991. The treatment with dextromethorphan of heroin addicts. In: Loimer, N., Schmid, R., Springer, A. (Eds.), Drug addiction and AIDS. Springer, Vienna, pp. 320-329.
70. Koyuncuoglu, H., 1995. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int. J. Clin. Pharmacol. Ther. 33, 13-19.
71. Koyuncuoglu, H., Saydam, B., 1990. The treatment of heroin addicts with dextromethorphan. A double- blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. 28, 147-152.
72. Kratzer, U., Schmidt, W.J., 1998. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neurosci. Lett. 252, 53-56.
73. Lett, B.T., 1989. Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology (Berlin) 98, 357-362.
74. Liljequist, S., 1991. The competitive NMDA receptor antagonist, CGP 39551, inhibits ethanol withdrawal seizures. Eur. J. Pharmacol. 192, 197-198.
75. Lin, N.L., Hubbard, J.I., 1995. An NMDA receptor antagonist reduces ethanol preference in untrained but not trained rats. Brain Res. Bull. 36, 421-424.
76. Lipton, S.A., Rosenberg, P.A., 1994. Mechanisms of disease: excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613-622.
77. Littleton, J., 1995. Acamprosate in alcohol dependence: how does it work? Addiction 90, 1179-1188.
78. Livezey, R.T., Pearce, L.B., Kornetsky, C., 1995. The effect of MK-801 and SCH23390 on the expression and sensitization of morphine-induced oral stereotypy. Brain Res. 692, 93-98.
79. Madamba, S.G., Schweitzer, P., Zieglgansberger, W., Siggins, G.R., 1996. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin. Exp. Res. 20, 651-658.
80. Markou, A., Kosten, T.R., Koob, G.F., 1998. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18, 135-174.
81. Mash, D.C., Kovera, C.A., Buck, B.E., Norenberg, M.D., Shapshak, P., Hearn, W.L., Sanchez-Ramos, J., 1998. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. N. Y. Acad. Sci. 844, 274-292.
82. Mattick, R.P., Hall, W., 1996. Are detoxification programmes effective? Lancet 347, 97-100.
83. McCaslin, P.P., Morgan, W.W., 1987. 2-Amino-7-phosphonoheptanoic acid, a selective antagonist of N-methyl-D-aspartate, prevents barbital withdrawal-induced convulsions and the elevation of cerebellar cyclic GMP in dependent rats. Neuropharmacology 26, 731-735.
84. Meil, W.M., See, R.E., 1997. Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self- administered cocaine. Behav. Brain Res. 87, 139-148.
85. Messenheimer, J., Mullens, E.L., Giorgi, L., Young, F., 1998. Safety review of adult clinical trial experience with lamotrigine. Drug Saf. 18, 281-296.
86. Morrisett, R.A., Rezvani, A.H., Overstreet, D., Janowsky, D.S., Wilson, W.A., Swartzwelder, H.S., 1990. MK-801 potently inhibits alcohol withdrawal seizures in rats. Eur. J. Pharmacol. 176, 103-105.
87. Mucha, R.F., Iversen, S.D., 1984. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology (Berlin) 82, 241-247.
88. Naassila, M., Hammoumi, S., Legrand, E., Durbin, P., Daoust, M., 1998. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin. Exp. Res. 22, 802-809.
89. Nestler, E.J., Aghajanian, G.K., 1997. Molecular and cellular basis of addiction. Science 278, 58-63.
90. Netzer, R., Pflimlin, P., Trube, G., 1993. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur. J. Pharmacol. 238, 209-216.
91. Nicholson, K.L., Jones, H.E., Balster, R.L., 1998. Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behav. Pharmacol. 9, 231-243.
92. O'Brien, C.P., Testa, T., O'Brien, T.J., Brady, J.P., Wells, B., 1977. Conditioned narcotic withdrawal in humans. Science 195, 1000-1002.
93. O'Brien, C.P., Childress, A.R., Ehrman, R., Robbins, S.J., 1998. Conditioning factors in drug abuse: can they explain compulsion? J. Psychopharmacol. 12, 15-22.
94. Ortiz, J., Fitzgerald, L.W., Charlton, M., Lane, S., Trevisan, L., Guitart, X., Shoemaker, W., Duman, R.S., Nestler, E.J., 1995. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 21, 289-298.
95. Piasecki, J., Koros, E., Dyr, W., Kostowski, W., Danysz, W., Bienkowski, P., 1998. Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur. J. Pharmacol. 354, 135-143.
96. Piazza, P.V., Deminiere, J.M., Le Moal, M., Simon, H., 1989. Factors that predict individual vulnerability to amphetamine self-administration. Science 245, 1511-1513.
97. Pierce, R.C., Meil, W.M., Kalivas, P.W., 1997. The NMDA antagonist, dizocilpine, enhances cocaine reinforcement without influencing mesoaccumbens dopamine transmission. Psychopharmacology (Berlin) 133, 188-195.
98. Popik, P., Danysz, W., 1997. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 280, 854-865.
99. Popik, P., Kolasiewicz, W., 1999. Mesolimbic NMDA receptors implicated in the expression of morphine reward. Naunyn-Schmiedebergs Arch. Pharmacol. 359, 288-294.
100. Popik, P., Kozela, E., 1999. Clinically available NMDA antagonist, memantine attenuates tolerance to analgesic effects of morphine in a mouse tail flick test. Pol. J. Pharmacol. 51, 223-231.
101. Popik, P., Skolnick, P., 1996. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53, 791-797.
102. Popik, P., Layer, R.T., Fossom, L., Benveniste, M., Getter-Douglas, B., Witkin, J.M., Skolnick, P., 1995a. NMDA antagonist properties of the putative anti-addicitive drug, ibogaine. J. Pharmacol. Exp. Ther. 275, 753-760.
103. Popik, P., Layer, R.T., Skolnick, P., 1995b. 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47, 235-253.
104. Popik, P., Mamczarz, J., Fraczek, M., Widla, G., Hesselink, M., Danysz, W., 1998. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology 37, 1033-1042.
105. Pudiak, C.M., Bozarth, M.A., 1993. L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine. Life Sci. 53, 1517-1524.
106. Pulvirenti, L., Balducci, C., Koob, G.F., 1996. Inhibition of nitric oxide synthesis reduces intravenous cocaine self-administration in the rat. Neuropharmacology 35, 1811-1814.
107. Pulvirenti, L., Balducci, C., Koob, G.F., 1997. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol. 321, 279-283.
108. Pulvirenti, L., Maldonado-Lopez, R., Koob, G.F., 1992. NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res. 594, 327-330.
109. al Qatari, M., Bouchenafa, O., Littleton, J., 1998. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin. Exp. Res. 22, 810-814.
110. Rabbani, M., Wright, J., Butterworth, A.R., Zhou, Q., Little, H.J., 1994. Possible involvement of NMDA receptor-mediated transmission in barbiturate physical dependence. Br. J. Pharmacol. 111, 89-96.
111. Rafi-Tari, S., Kalant, H., Liu, J.F., Silver, I., Wu, P.H., 1996. Dizocilpine prevents the development of tolerance to ethanol-induced error on a circular maze test. Psychopharmacology (Berlin) 125, 23-32.
112. Ranaldi, R., French, E., Roberts, D.C., 1996. Systemic pretreatment with MK-801 (dizocilpine) increases breaking points for self-administration of cocaine on a progressive-ratio schedule in rats. Psychopharmacology (Berlin) 128, 83-88.
113. Ranaldi, R., Bauco, P., Wise, R.A., 1997. Synergistic effects of cocaine and dizocilpine (MK-801) on brain stimulation reward. Brain Res. 760, 231-237.
114. Rassnick, S., D'Amico, E., Riley, E., Pulvirenti, L., Zieglgansberger, W., Koob, G.F., 1992. GABA and nucleus accumbens glutamate neurotransmission modulate ethanol self-administration in rats. Ann. N. Y. Acad. Sci. 654, 502-505.
115. Robinson, T.E., Berridge, K.C., 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291.
116. Rosen, M.I., Kosten, T.R., 1998. The effect of cycloserine on naloxone-precipitated opiate withdrawal. NIDA Res. Monogr. 178, 308.
117. Rosen, M.I., McMahon, T.J., Woods, S.W., Pearsall, H.R., Kosten, T.R., 1996. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur. J. Pharmacol. 307, 251-257.
118. Rosen, M.I., Persall, H.R., Kosten, T.R., 1998. The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Depend. 52, 173-176.
119. Schenk, S., Valadez, A., McNamara, C., House, D.T., Higley, D., Bankson, M.G., Gibbs, S., Horger, B.A., 1993a. Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology (Berlin) 111, 332-338.
120. Schenk, S., Valadez, A., Worley, C.M., Mcnamara, C., 1993b. Blockade of the acquisition of cocaine self-administration by the NMDA antagonist MK-801 (dizocilpine). Behav. Pharmacol. 4 (6), 652-659.
121. Schneider, N.G., Jarvik, M.E., Forsythe, A.B., 1984. Nicotine vs. placebo gum in the alleviation of withdrawal during smoking cessation. Addict. Behav. 9, 149-156.
122. Schulteis, G., Gold, L.H., Koob, G.F., 1997. Preclinical behavioral models for addressing unmet needs in opiate addiction. Semin. Neurosci. 9, 94-109.
123. Segal, D.S., Kuczenski, R., Florin, S.M., 1995. Does dizocilpine (MK-801) selectively block the enhanced responsiveness to repeated amphetamine administration? Behav. Neurosci. 109, 532-546.
124. Semenova, S., Kuzmin, A.V., Danysz, W., Bespalov, A.Y., 1999. Low affinity NMDA receptor channel blockers inhibit initiation of intravenous morphine self-administration in naive mice. Eur. J. Pharmacol. 378, 1-8.
125. Sershen, H., Hashim, A., Lajtha, A., 1997. Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Brain Res. Bull. 42, 161-168.
126. Shelton, K.L., Balster, R.L., 1997. Effects of gamma-aminobutyric acid agonists and N-methyl-D-aspartate antagonists on a multiple schedule of ethanol and saccharin self-administration in rats. J. Pharmacol. Exp. Ther. 280, 1250-1260.
127. Sheppard, S.G., 1994. A preliminary investigation of ibogaine: Case reports and recommendations for further study. J. Subst. Abuse Treat. 11 (4), 379.
128. Shoaib, M., Stolerman, I.P., 1996. The NMDA antagonist dizocilpine (MK801) attenuates tolerance to nicotine in rats. J. Psychopharmacol. 10, 214-218.
129. Shoaib, M., Benwell, M.E., Akbar, M.T., Stolerman, I.P., Balfour, D.J., 1994. Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. Br. J. Pharmacol. 111, 1073-1080.
130. Shoaib, M., Shippenberg, T.S., Goldberg, S.R., Schindler, C.W., 1995. Behavioral studies with the glycine partial agonist ( + )-HA966 on cocaine-induced locamotor activity and reinforcement. Behav. Pharmacol. 6, 568-576.
131. Shoaib, M., Schindler, C.W., Goldberg, S.R., Pauly, J.R., 1997. Behavioural and biochemical adaptations to nicotine in rats: influence of MK801, an NMDA receptor antagonist. Psychopharmacology (Berlin) 134, 121-130.
132. Shoptaw, S., Ling, W., Kintaudi, K. Rawson, R.A., 1998. Amantadine hydrochloride is effective treatment for cocaine dependence. Paper presented at the College on Problems of Drug Dependence. Sixtieth Annual Meeting, Scottsdale, Arizona.
133. Silagy, C., Mant, D., Fowler, G., Lodge, M., 1994. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 343, 139-142.
134. Smith, D.E., Wesson, D.R., 1994. Benzodiazepines and other sedative-hypnotics. In: Kleber, H.D., Galanter, M. (Eds.), American Psychiatric Press Textbook of Substance Abuse Treatment. American Psychiatric Press, Washington DC, pp. 179-190.
135. Spanagel, R., Zieglgansberger, W., 1997. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol. Sci. 18, 54-59.
136. Spanagel, R., Holter, S.M., Allingham, K., Landgraf, R., Zieglgansberger, W., 1996a. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur. J. Pharmacol. 305, 39-44.
137. Spanagel, R., Putzke, J., Stefferl, A., Schobitz, B., Zieglgansberger, W., 1996b. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur. J. Pharmacol. 305, 45-50.
138. Spanagel, R., Sillaber, I., Zieglgansberger, W., Corrigall, W.A., Stewart, J., Shaham, Y., 1998. Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology (Berlin) 139, 391-401.
139. Steppuhn, K.G., Turski, L., 1993. Diazepam dependence prevented by glutamate antagonists. Proc. Natl. Acad. Sci. USA 90, 6889-6893.
140. Stewart, J., Druhan, J.P., 1993. Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. Psychopharmacology (Berlin) 110, 125-132.
141. Szabo, G., Tabakoff, B., Hoffman, P.L., 1994. The NMDA receptor antagonist dizocilpine differentially affects environment-dependent and environment-independent ethanol tolerance. Psychopharmacology (Berlin) 113, 511-517.
142. Tennant, F.S., Jr. Sagherian, A.A., 1987. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Intern. Med. 147, 109-112.
143. Thompson, D.F., 1992. Amantadine in the treatment of cocaine withdrawal. Ann. Pharmacother. 26, 933-934.
144. Tiseo, P.J., Inturrisi, C.E., 1993. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264, 1090-1096.
145. Trujillo, K.A., Akil, H., 1991. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251, 85-87.
146. Tzschentke, T.M., Schmidt, W.J., 1995. N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett. 193, 37-40.
147. Tzschentke, T.M., Schmidt, W.J., 1997. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization. Behav. Brain Res. 84, 99-107.
148. Vaupel, D.B., Kimes, A.S., London, E.D., 1997. Further in vivo studies on attenuating morphine withdrawal: isoform-selective nitric oxide synthase inhibitors differ in efficacy. Eur. J. Pharmacol. 324, 11-20.
149. Watson, G.B., Bolanowski, M.A., Baganoff, M.P., Deppeler, C.L., Lanthorn, T.H., 1990. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 510, 158-160.
150. Weddington, W.W. Jr, Brown, B.S., Haertzen, C.A., Hess, J.M., Mahaffey, J.R., Kolar, A.F., Jaffe, J.H., 1991. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse 17, 137-152.
151. Wilde, M.I., Wagstaff, A.J., 1997. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53, 1038-1053.
152. Wolf, M.E., 1998. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. Neurobiol. 54, 679-720.
153. Wolf, M.E., Jeziorski, M., 1993. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization. Brain Res. 613, 291-294.
154. Wolf, M.E., Khansa, M.R., 1991. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res. 562, 164-168.
155. Wu, P.H., Mihic, S.J., Liu, J.F., Le, A.D., Kalant, H., 1993. Blockade of chronic tolerance to ethanol by the NMDA antagonist, ( + )-MK-801. Eur. J. Pharmacol. 231, 157-164.
156. Zeise, M.L., Kasparov, S., Capogna, M., Zieglgansberger, W., 1993. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 231, 47-52.
157. Ziedonis, D.M., Kosten, T.R., 1991. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J. Psychoactive Drugs 23, 417-425.